AAAAAA

   
Results: 1-19 |
Results: 19
THE ABSOLUTE BIOAVAILABILITY AND EFFECT OF FOOD ON THE PHARMACOKINETICS OF ZOLMITRIPTAN IN HEALTHY-VOLUNTEERS
Authors: SEABER EJ PECK RW SMITH DA ALLANSON J HEFTING NR VANLIER JJ SOLLIE FAE WEMER J JONKMAN JHG
Citation: Ej. Seaber et al., THE ABSOLUTE BIOAVAILABILITY AND EFFECT OF FOOD ON THE PHARMACOKINETICS OF ZOLMITRIPTAN IN HEALTHY-VOLUNTEERS, British journal of clinical pharmacology, 46(5), 1998, pp. 433-439
EFFECT OF FOOD AND GENDER ON THE PHARMACOKINETICS OF TUCARESOL IN HEALTHY-VOLUNTEERS
Authors: PECK RW WOOTTON R WIGGS R LAYTON G POSNER J
Citation: Rw. Peck et al., EFFECT OF FOOD AND GENDER ON THE PHARMACOKINETICS OF TUCARESOL IN HEALTHY-VOLUNTEERS, British journal of clinical pharmacology, 46(1), 1998, pp. 83-86
LACK OF INTERACTION BETWEEN VALACICLOVIR, THE L-VALYL ESTER OF ACYCLOVIR, AND DIGOXIN
Authors: SOULLAWTON JH WEATHERLEY BC POSNER J LAYTON G PECK RW
Citation: Jh. Soullawton et al., LACK OF INTERACTION BETWEEN VALACICLOVIR, THE L-VALYL ESTER OF ACYCLOVIR, AND DIGOXIN, British journal of clinical pharmacology, 45(1), 1998, pp. 87-89
THE PHARMACODYNAMICS AND PHARMACOKINETICS OF THE 5HT(1B 1D)-AGONIST ZOLMITRIPTAN IN HEALTHY-YOUNG AND ELDERLY MEN AND WOMEN/
Authors: PECK RW SEABER EJ DIXON RM LAYTON GR WEATHERLEY BC JACKSON SHD ROLAN PE POSNER J
Citation: Rw. Peck et al., THE PHARMACODYNAMICS AND PHARMACOKINETICS OF THE 5HT(1B 1D)-AGONIST ZOLMITRIPTAN IN HEALTHY-YOUNG AND ELDERLY MEN AND WOMEN/, Clinical pharmacology and therapeutics, 63(3), 1998, pp. 342-353
LACK OF INTERACTION BETWEEN ORAL DIHYDROERGOTAMINE AND THE NOVEL ANTIMIGRAINE COMPOUND ZOLMITRIPTAN IN HEALTHY-VOLUNTEERS
Authors: VERONESE L GILLOTIN C MARIONGALLOIS R WEATHERLEY BC THEBAULT JJ GUILLAUME M PECK RW
Citation: L. Veronese et al., LACK OF INTERACTION BETWEEN ORAL DIHYDROERGOTAMINE AND THE NOVEL ANTIMIGRAINE COMPOUND ZOLMITRIPTAN IN HEALTHY-VOLUNTEERS, Clinical drug investigation, 14(3), 1997, pp. 217-220
NO NEED TO ADJUST THE DOSE OF 311C90 (ZOLMITRIPTAN), A NOVEL ANTIMIGRAINE TREATMENT, IN PATIENTS WITH RENAL-FAILURE NOT REQUIRING DIALYSIS
Authors: GILLOTIN C BAGNIS C MAMET JP PECK RW DERAY G
Citation: C. Gillotin et al., NO NEED TO ADJUST THE DOSE OF 311C90 (ZOLMITRIPTAN), A NOVEL ANTIMIGRAINE TREATMENT, IN PATIENTS WITH RENAL-FAILURE NOT REQUIRING DIALYSIS, International journal of clinical pharmacology and therapeutics, 35(11), 1997, pp. 522-526
THE INTERACTION BETWEEN PROPRANOLOL AND THE NOVEL ANTIMIGRAINE AGENT ZOLMITRIPTAN (311C90)
Authors: PECK RW SEABER EJ DIXON R GILLOTIN CG WEATHERLEY BC LAYTON G POSNER J
Citation: Rw. Peck et al., THE INTERACTION BETWEEN PROPRANOLOL AND THE NOVEL ANTIMIGRAINE AGENT ZOLMITRIPTAN (311C90), British journal of clinical pharmacology, 44(6), 1997, pp. 595-599
THE ABSOLUTE BIOAVAILABILITY AND METABOLIC DISPOSITION OF THE NOVEL ANTIMIGRAINE COMPOUND ZOLMITRIPTAN (311C90)
Authors: SEABER E ON N DIXON RM GIBBENS M LEAVENS WJ LIPTROT J CHITTICK G POSNER J ROLAN PE PECK RW
Citation: E. Seaber et al., THE ABSOLUTE BIOAVAILABILITY AND METABOLIC DISPOSITION OF THE NOVEL ANTIMIGRAINE COMPOUND ZOLMITRIPTAN (311C90), British journal of clinical pharmacology, 43(6), 1997, pp. 579-587
THE PHARMACOKINETICS AND EFFECTS ON BLOOD-PRESSURE OF MULTIPLE DOSES OF THE NOVEL ANTIMIGRAINE DRUG ZOLMITRIPTAN (311C90) IN HEALTHY-VOLUNTEERS
Authors: DIXON R GILLOTIN C GIBBENS M POSNER J PECK RW
Citation: R. Dixon et al., THE PHARMACOKINETICS AND EFFECTS ON BLOOD-PRESSURE OF MULTIPLE DOSES OF THE NOVEL ANTIMIGRAINE DRUG ZOLMITRIPTAN (311C90) IN HEALTHY-VOLUNTEERS, British journal of clinical pharmacology, 43(3), 1997, pp. 273-281
THE NOVEL ANTIMIGRAINE COMPOUND ZOLMITRIPTAN (ZOMIG 311C90) HAS NO CLINICALLY SIGNIFICANT INTERACTIONS WITH PARACETAMOL OR METOCLOPRAMIDE
Authors: SEABER EJ RIDOUT G LAYTON G POSNER J PECK RW
Citation: Ej. Seaber et al., THE NOVEL ANTIMIGRAINE COMPOUND ZOLMITRIPTAN (ZOMIG 311C90) HAS NO CLINICALLY SIGNIFICANT INTERACTIONS WITH PARACETAMOL OR METOCLOPRAMIDE, European Journal of Clinical Pharmacology, 53(3-4), 1997, pp. 229-234
SEASONAL FLIGHT PATTERNS OF BARK AND AMBROSIA BEETLES (COLEOPTERA, SCOLYTIDAE) IN NORTHEASTERN OREGON
Authors: PECK RW EQUIHUAMARTINEZ A ROSS DW
Citation: Rw. Peck et al., SEASONAL FLIGHT PATTERNS OF BARK AND AMBROSIA BEETLES (COLEOPTERA, SCOLYTIDAE) IN NORTHEASTERN OREGON, The Pan-Pacific entomologist, 73(4), 1997, pp. 204-212
PHARMACOKINETICS OF NETIVUDINE IN HEMODIALYSIS-PATIENTS
Authors: LEROY F GODIN M LEGALLICLER B FILLASTRE JP BIDAULT R POSNER J PECK RW
Citation: F. Leroy et al., PHARMACOKINETICS OF NETIVUDINE IN HEMODIALYSIS-PATIENTS, Journal of antimicrobial chemotherapy, 38(5), 1996, pp. 913-915
PHARMACOKINETICS OF NETIVUDINE, A POTENT ANTI-VARICELLA ZOSTER VIRUS DRUG, IN PATIENTS WITH RENAL IMPAIRMENT
Authors: FILLASTRE JP GODIN M LEGALLICIER B CHRETIEN P BIDAULT R GILLOTIN C WOOTON R POSNER J PECK RW
Citation: Jp. Fillastre et al., PHARMACOKINETICS OF NETIVUDINE, A POTENT ANTI-VARICELLA ZOSTER VIRUS DRUG, IN PATIENTS WITH RENAL IMPAIRMENT, Journal of antimicrobial chemotherapy, 37(5), 1996, pp. 965-974
MULTIPLE-DOSE NETIVUDINE, A POTENT ANTI-VARICELLA ZOSTER VIRUS AGENT,IN HEALTHY ELDERLY VOLUNTEERS AND PATIENTS WITH SHINGLES
Authors: PECK RW CROME P WOOD MJ MCKENDRICK MW BANNISTER B MANDAL BK CROOKS RJ
Citation: Rw. Peck et al., MULTIPLE-DOSE NETIVUDINE, A POTENT ANTI-VARICELLA ZOSTER VIRUS AGENT,IN HEALTHY ELDERLY VOLUNTEERS AND PATIENTS WITH SHINGLES, Journal of antimicrobial chemotherapy, 37(3), 1996, pp. 583-597
THE BIOAVAILABILITY AND DISPOSITION OF 1-(BETA-D-ARABINOFURANOSYL)-5-(1-PROPYNYL)URACIL (882C87), A POTENT, NEW ANTI-VARICELLA ZOSTER VIRUSAGENT
Authors: PECK RW WOOTTON R LEE DR JACKSON SHD POSNER J
Citation: Rw. Peck et al., THE BIOAVAILABILITY AND DISPOSITION OF 1-(BETA-D-ARABINOFURANOSYL)-5-(1-PROPYNYL)URACIL (882C87), A POTENT, NEW ANTI-VARICELLA ZOSTER VIRUSAGENT, British journal of clinical pharmacology, 39(2), 1995, pp. 143-149
PHARMACOKINETICS AND TOLERABILITY OF SINGLE ORAL DOSES OF 882C87, A POTENT, NEW ANTI-VARICELLA-ZOSTER VIRUS AGENT, IN HEALTHY-VOLUNTEERS
Authors: PECK RW WEATHERLEY BC WOOTTON R CROME P HOLDICH TAH POSNER J
Citation: Rw. Peck et al., PHARMACOKINETICS AND TOLERABILITY OF SINGLE ORAL DOSES OF 882C87, A POTENT, NEW ANTI-VARICELLA-ZOSTER VIRUS AGENT, IN HEALTHY-VOLUNTEERS, Antimicrobial agents and chemotherapy, 39(1), 1995, pp. 20-27
THE TOLERABILITY, PHARMACOKINETICS AND LACK OF EFFECT ON PLASMA-CHOLESTEROL OF 447C88, AN ACYLCOA-CHOLESTEROL-ACYL-TRANSFERASE (ACAT) INHIBITOR WITH LOW BIOAVAILABILITY, IN HEALTHY-VOLUNTEERS
Authors: PECK RW WIGGS R POSNER J
Citation: Rw. Peck et al., THE TOLERABILITY, PHARMACOKINETICS AND LACK OF EFFECT ON PLASMA-CHOLESTEROL OF 447C88, AN ACYLCOA-CHOLESTEROL-ACYL-TRANSFERASE (ACAT) INHIBITOR WITH LOW BIOAVAILABILITY, IN HEALTHY-VOLUNTEERS, European Journal of Clinical Pharmacology, 49(3), 1995, pp. 243-249
EXAMINATION OF SOME FACTORS RESPONSIBLE FOR A FOOD-INDUCED INCREASE IN ABSORPTION OF ATOVAQUONE
Authors: ROLAN PE MERCER AJ WEATHERLEY BC HOLDICH T MEIRE H PECK RW RIDOUT G POSNER J
Citation: Pe. Rolan et al., EXAMINATION OF SOME FACTORS RESPONSIBLE FOR A FOOD-INDUCED INCREASE IN ABSORPTION OF ATOVAQUONE, British journal of clinical pharmacology, 37(1), 1994, pp. 13-20
PRELIMINARY PHARMACOKINETICS AND SAFETY OF 882C87 IN PATIENTS WITH HERPES-ZOSTER
Authors: WOOD MJ MCKENDRICK MW BANNISTER B MANDAL BK PECK RW CROOKS RJ
Citation: Mj. Wood et al., PRELIMINARY PHARMACOKINETICS AND SAFETY OF 882C87 IN PATIENTS WITH HERPES-ZOSTER, Journal of medical virology, 1993, pp. 154-157
Risultati: 1-19 |